PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-27.41%
Both companies show declining cash positions (-27.41% vs TRVN's -38.40%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-27.41%
Cash + STI yoy ≥ 1.5x TRVN's -2.31%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.07%
Other current assets growth < half of TRVN's 160.46%. David Dodd sees a leaner approach to short-term items.
-28.37%
≥ 1.5x TRVN's -0.72%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
1187.39%
≥ 1.5x TRVN's 163.95%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.01%
Less than half of TRVN's 0.15%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
252.00%
≥ 1.5x TRVN's 118.44%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-17.83%
Below half of TRVN's 7.65%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-8.53%
Less than half of TRVN's -74.72%. David Dodd sees a more disciplined AP approach or lower volume.
-29.62%
Less than half of TRVN's 18.56%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
12.29%
Higher Deferred Revenue (Current) Growth compared to TRVN's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
-3.44%
Above 1.5x TRVN's -1.62%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7668.72%
Above 1.5x TRVN's 6.85%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
13.42%
Above 1.5x TRVN's 0.99%. Michael Burry sees a potential leverage warning sign.
2.97%
Less than half of TRVN's 12.20%. David Dodd sees fewer share issuances vs. competitor.
-3.03%
≥ 1.5x TRVN's -1.33%. David Dodd sees higher yoy retained profits than competitor.
25.83%
Less than half of TRVN's 133.33%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-39.38%
Below half TRVN's 11.71%. Michael Burry sees potential underperformance in building shareholder capital.
-17.83%
Below half TRVN's 7.65%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
499.58%
Above 1.5x TRVN's 33.24%. Michael Burry sees a major jump. Investigate leverage rationale.
37.73%
Less than half of TRVN's 118.79%. David Dodd sees better deleveraging or stronger cash buildup than competitor.